Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Charles River reaffirms commitment to the future of drug discovery by
advancing the Company’s integrated, innovative early-stage platform

WILMINGTON, Mass. & SAN FRANCISCO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CRL&src=ctag” target=”_blank”gt;$CRLlt;/agt; lt;a href=”https://twitter.com/hashtag/LIFEatCRL?src=hash” target=”_blank”gt;#LIFEatCRLlt;/agt;–Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise,
Inc. today announced the formation of a strategic alliance that offers
clients access to Atomwise’s artificial intelligence (AI)-powered,
structure-based, drug design technology, which allows scientists to
predict how well a small molecule will bind to a target protein of
interest. By removing sole reliance on empirical screening, AI enables
drug researchers to test an extremely large and diverse chemical space
in a matter of days and move through the optimization process quickly by
focusing only on those compounds predicted to have improved
target-binding attributes.


This alliance combines two industry-leading drug discovery platforms:
Atomwise’s AI technology and Charles River’s unique portfolio of
end-to-end drug discovery and early-stage development capabilities and
expertise. Leveraging Atomwise’s AI technology and Charles River’s
integrated drug discovery platform has the potential to significantly
streamline the hit discovery, hit-to-lead, and lead optimization process
for clients’ research efforts.

Through the collaboration, Charles River will have access to Atomwise’s
AI technology to use with their existing portfolio of drug discovery
services. Atomwise’s patented technology can analyze billions of
compounds and screen challenging target proteins in the small molecule
drug discovery process. The advantages of Atomwise’s AI technology will
provide Charles River’s clients with the opportunity to efficiently
screen billions, and evaluate thousands, of compounds to optimize
potency, selectivity, and toxicity during hit and lead identification
before committing resources to assays or syntheses.

As a result, Charles River’s clients can expect increased efficiency and
diversity in the drug discovery process, ultimately reducing the
expected timeline for an integrated drug discovery project and expanding
the chemical space examined.

Furthering a Commitment to Flexible, Efficient Drug Discovery

The Atomwise AI technology platform will allow Charles River to enhance
standard approaches to the identification and optimization of small
molecules. This represents another progressive step for Charles River as
the company has completed a series of technology partnerships that both
elevate and expand the reach of its portfolio, providing Charles River’s
clients with next-generation discovery platforms to accelerate programs
into the clinic.

Approved Quotes

  • “As Charles River continues to expand its early drug discovery
    portfolio, innovative solutions, including Atomwise’s AI technology,
    enable us to provide clients with a comprehensive, integrated platform
    for their early-stage drug research. By cutting time out of each stage
    of the drug discovery process, we enable our clients to deliver novel
    therapeutics to patients more efficiently and effectively.” –James
    Foster, Chairman, President and Chief Executive Officer of Charles
    River Laboratories
  • “We are proud to put this cutting-edge technology in the hands of our
    scientists and clients. The potential for both time savings and
    program optimization represents an attractive value proposition for
    our clients.” –Birgit Girshick, Corporate Executive Vice President,
    Discovery and Safety Assessment of Charles River Laboratories
  • “We went through a rigorous process in selecting a CRO. We needed a
    partner that matched our commitment to quality and integrity because
    trust is critical for drug discovery. A global leader like Charles
    River, trusted around the world for high quality services, was a
    perfect fit for Atomwise.” –Abraham Heifets, CEO of Atomwise

About Atomwise

Atomwise, Inc. invented the first deep learning AI technology for
structure-based small molecule drug discovery. Created in 2012, today
Atomwise performs hundreds of projects per year in partnership with some
of the world’s largest pharmaceutical and agrochemical companies, as
well as more than one hundred universities and hospitals in 19
countries. Atomwise has raised over $50 million from leading venture
capital firms to support the development and application of its AI
technology.

About Charles River

Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Contact:
Charles River
Todd
Spencer
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com

Media Contacts:

Charles River
Amy Cianciaruso
Corporate
Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com

Atomwise
Sara Dunn
202-591-4045
sdunn@jpa.com